Mark J Rosenblum

CIK 1329154 · Exec VP Finance, CFO · last filed 2025-11-20

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

2

Total Filings

32

Lifetime Open-Market Net

$110.0K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Salarius Pharmaceuticals, Inc. (SLRX) Delisted Exec VP Finance, CFO 20,177 $0.84 $16.9K $62.0K 20 2025-11-20
Ayala Pharmaceuticals, Inc. (ADXS.W) Delisted Chief Financial Officer 113,774 $48.0K 4 2014-02-04

Recent Filings · Page 3 of 4

32 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2014-02-04 Ayala Pharmaceuticals, Inc. (ADXS.W) Delisted Mixed +482 -$216 EDGAR
2014-01-09 Ayala Pharmaceuticals, Inc. (ADXS.W) Delisted Mixed +1,420 -$6.3K EDGAR
2014-01-09 Ayala Pharmaceuticals, Inc. (ADXS.W) Delisted Mixed +91,676 -$33.5K EDGAR
2013-10-28 Ayala Pharmaceuticals, Inc. (ADXS.W) Delisted Buy (P) +12,000 $48.0K EDGAR
2013-07-10 Grant (A) $0
2012-05-16 Mixed +686,275 $0
2011-11-10 Grant (A) $0
2011-11-02 Grant (A) $0
2010-10-18 Grant (A) $0
2009-03-09 Grant (A) +65,000 $0
Showing 2130 of 32
Page 3 of 4
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.